- 最后登录
- 2012-5-16
- 在线时间
- 779 小时
- 寄托币
- 2508
- 声望
- 95
- 注册时间
- 2009-9-27
- 阅读权限
- 35
- 帖子
- 23
- 精华
- 0
- 积分
- 1754
- UID
- 2704028
 
- 声望
- 95
- 寄托币
- 2508
- 注册时间
- 2009-9-27
- 精华
- 0
- 帖子
- 23
|
发表于 2010-3-22 22:00:56
|显示全部楼层
TOPIC: ARGUMENT5 - The following appeared in the business section of a newspaper.
"Given that the number of people in our country with some form of arthritis is expected to rise from 40 million to 60 million over the next twenty years, pharmaceutical companies that produce drugs for the treatment of arthritis should be very profitable. Many analysts believe that in ten years Becton Pharmaceuticals, which makes Xenon, the best-selling drug treatment for arthritis, will be the most profitable pharmaceutical company. But the patent on Xenon expires in three years, and other companies will then be able to produce a cheaper version of the drug. Thus, it is more likely that in ten years the most profitable pharmaceutical company will be Perkins Pharmaceuticals, maker of a new drug called Xylan, which clinical studies show is preferred over Xenon by seven out of ten patients suffering from the most extreme cases of arthritis."
WORDS: 299 TIME: 00:30:00 DATE: 2010/3/22 17:21:12
The author draws a conclusion that pharmaceutical companies would be profitable if they produce drugs for treating arthritis. However, there are some logical fallacies that make this idea untenable, some of which I would point out as below.
To begin with, the expiration of the patent on Xenon has little to do with Becton Pharmaceuticals would not produce other medications to treat arthritis. With the experience of Xenon, in all likelihood, it would produce at least similar drugs treating arthritis. Also, it is likely for them to asking for another patent. And customers are more likely to trust the companies and buy its drugs. For that matter, it is possible that other companies would not be profitable a lot since they are not as trustworthy as Becton Pharmaceutical.
In addition, the clinical studies demonstrate only a part of the effect of Xylan. In the study, seven out of ten patients who preferred Xylan over Xenon is suffering from the most extreme cases of arthritic. There still exist other patients who have lighter arthritis. Perhaps, Xylan does not work effectively on that type of patients. Thus, patients with lighter arthritis might choose other type of meditations instead of Xylan, resulting in Perkins' unprofitable.
Finally, even assuming Becton will not produce new kind of arthritis drugs and Xenon work effectively on all kinds of arthritis patients, whether Perkins could be profitable still remains to be seen. Profit is a result based on sales, prices, workers salaries and the like. To make a conclusion, taking every relative element into consideration is necessary. Whether Xylan would sell well? Whether Xylan's price would be too low for the pharmaceutical to gain extra money? Whether workers' salaries are too high? Before a whole evaluation, any harsh conclusion would be unpersuasive.
Therefore, the conclusion is untenable as it stands. Whether Becton Pharmaceutical will stop producing arthritis medicine, whether Xylan work on light arthritis, and whether Becton could truly benefit from Xylan need more direct evidence to prove. |
|